Crossmark

Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance)

Crossref DOI link: https://doi.org/10.1186/s13058-025-01963-5

Published Online: 2025-02-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Marks, Jeffrey R.

Zhang, Dadong

Hardman, Timothy

Chen, Yunn-yi

Hall, Allison

Simpson, Lunden

Hieken, Tina

Bedrosian, Isabelle

Price, Elissa

Sheng, Jeff

Dai, Yanwan

Lee, Marissa

Sibley, Alexander B.

Owzar, Kouros

Hwang, E. Shelley
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01439711 at ClinicalTrials.gov

Documents that mention this clinical trial

Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance)
https://doi.org/10.1186/s13058-025-01963-5
Funding

Funding for this research was provided by:

NIH/NCI to the Alliance for Clinical Trials in Oncology (U10CA180882)

Breast Cancer Research Foundation
License Information

Text and Data Mining valid from 2025-02-20

Version of Record valid from 2025-02-20
More Information

Article History

Received: 11 June 2024

Accepted: 11 January 2025

First Online: 20 February 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below